CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 135 participants.

Also called NCT06959121

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 135 participants (planned count) (from the registry)
Sponsor
  • Avania Registry lists this organization as a collaborator
Registry
  • NCT NCT06959121
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06959121. Allocation not applicable; no masking; primary purpose treatment. Start 2025-10-23 (actual); primary completion 2027-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
Acronym
NANOCLAMP-AF
Condition
Maze Procedure
Condition
AF
Condition
Ablation
Intervention (Device)
CellFX® nsPFA™ Cardiac Surgery System
Lead sponsor
Pulse Biosciences, Inc. (class: industry)
Collaborator
Avania (class: industry)

Record details

Record id
cardio:ct-nct06959121
Content hash
8b2906febbc3bc78b5769b8f90ced10f9ca9a4fc0791b1f4de008f23a13b5b90